![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » AstraZeneca’s Farxiga Approved for Heart Failure in Type 2 Diabetes Patients
AstraZeneca’s Farxiga Approved for Heart Failure in Type 2 Diabetes Patients
October 29, 2019
AstraZeneca received the FDA’s approval for Farxiga (dapagliflozin) to reduce the risk of hospitalization for heart failure in adults with type 2 diabetes and established cardiovascular disease or multiple cardiovascular risk factors.
The first-in-class, oral once-daily drug is indicated as both a monotherapy and as a combination therapy for improving glycemic control, in addition to weight loss and reducing blood pressure, alongside dieting and exercise in adult type 2 diabetes patients.
The drug “now offers the opportunity for physicians to act sooner and reduce the risk of hospitalization for heart failure,” an AZ spokesperson said.
Upcoming Events
-
21Oct